These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge. Frascaro F; Bianchi N; Sanguettoli F; Marchini F; Meossi S; Zanarelli L; Tonet E; Serenelli M; Guardigli G; Campo G; Calabrò L; Pavasini R J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137806 [TBL] [Abstract][Full Text] [Related]
12. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102 [TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients. Van Mol P; Donders E; Lambrechts D; Wauters E Int Rev Cell Mol Biol; 2024; 382():181-206. PubMed ID: 38225103 [TBL] [Abstract][Full Text] [Related]
14. Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy. Buehning F; Lerchner T; Vogel J; Hendgen-Cotta UB; Totzeck M; Rassaf T; Michel L Basic Res Cardiol; 2024 Jul; ():. PubMed ID: 39039301 [TBL] [Abstract][Full Text] [Related]
15. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors. Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A Front Immunol; 2022; 13():779691. PubMed ID: 35558065 [TBL] [Abstract][Full Text] [Related]
16. Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation. Bockstahler M; Fischer A; Goetzke CC; Neumaier HL; Sauter M; Kespohl M; Müller AM; Meckes C; Salbach C; Schenk M; Heuser A; Landmesser U; Weiner J; Meder B; Lehmann L; Kratzer A; Klingel K; Katus HA; Kaya Z; Beling A Circulation; 2020 Jun; 141(23):1885-1902. PubMed ID: 32160764 [TBL] [Abstract][Full Text] [Related]
17. Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. Ronen D; Bsoul A; Lotem M; Abedat S; Yarkoni M; Amir O; Asleh R Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455289 [TBL] [Abstract][Full Text] [Related]
18. Tumor immune checkpoints and their associated inhibitors. Gao Z; Ling X; Shi C; Wang Y; Lin A J Zhejiang Univ Sci B; 2022 Oct; 23(10):823-843. PubMed ID: 36226537 [TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: Tan S; Day D; Nicholls SJ; Segelov E JACC CardioOncol; 2022 Dec; 4(5):579-597. PubMed ID: 36636451 [TBL] [Abstract][Full Text] [Related]
20. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]